Endothelial Function as a Marker for Blood Pressure Control Among Hypertensive Diabetic Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Valentin Yurkevich, Soroka University Medical Center
ClinicalTrials.gov Identifier:
NCT00337038
First received: June 14, 2006
Last updated: June 21, 2012
Last verified: June 2012
  Purpose

Our aim is to examine the influence of blood pressure and glycemic control together with N-acetylcystein utilization on the endothelia function of hypertensive diabetic patient.The study population will include 50 diabetic patient with uncontrolled hypertention that will be recruited from the Hypertension Clinic of Soroka University Medical Center.


Condition Intervention Phase
Hypertension
Diabetes Mellitus Type 2
Drug: N-acetylcystein(drug)
Phase 0

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic

Resource links provided by NLM:


Further study details as provided by Soroka University Medical Center:

Primary Outcome Measures:
  • endothelial function [ Time Frame: half of year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • blood pressure and glycemic control [ Time Frame: half of year ] [ Designated as safety issue: Yes ]

Enrollment: 50
Study Start Date: June 2006
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: N-acetylcystein(drug)
    p.O t.Siran 200mg x1 during one weak
    Other Name: siran
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diabetic patients with uncontrolled hypertension that will be recruited from the Hypertension Clinic of Soroka University Medical Center

Exclusion Criteria:

  • Pregnancy,secondary hypertention,malignancy or other serious illness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00337038

Sponsors and Collaborators
Soroka University Medical Center
Investigators
Principal Investigator: Ester Paran, MD Hypertension Clinic of Soroka University Medical Center
Principal Investigator: Ester Paran, MD Soroka University Medical Center
  More Information

No publications provided

Responsible Party: Valentin Yurkevich, Dr Yurkevich, Soroka University Medical Center
ClinicalTrials.gov Identifier: NCT00337038     History of Changes
Other Study ID Numbers: sor431706ctil
Study First Received: June 14, 2006
Last Updated: June 21, 2012
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Hypertension
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on July 20, 2014